Links to all the late-breaking structural heart studies at TVT 2022
The 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit took place in Chicago June 8-10 and featured 12 late-breaking clinical studies. Below are links to more information on all of the late-breaking studies.
The annual meeting by the Cardiovascular Research Foundation (CRF) covers cutting-edge research and techniques for structural heart interventions and techniques for structural heart interventions.
The late-breakers were:
TVT Late-Breaking Clinical Science
Clinical Science Theater, Wednesday, June 8, 2022, 10:30 a.m. – noon CDT
• First Report of Outcomes of TEER in Patients With Endocardial Leads: Insights From TRILUMINATE and bRIGHT Clinical Trials. Presented by Georg Nickenig.
• Transcatheter Aortic Valve Replacement With the Self-Expanding Acurate neo2: Hemodynamic Performance and Clinical Outcomes. Presented by Andrea Scotti.
• Contemporary Outcomes of TMVR With Sapien 3/Ultra for Failed Surgical Repairs With Annuloplasty Rings in the U.S. Presented by James McCabe.
• One-Year Outcomes in Patients With Secondary MR Outside the COAPT Criteria: From the MitraClip Global EXPAND Study. Presented by Gilbert Tang.
• Explant Versus Redo TAVR After TAVR Failure: Outcomes From the EXPLANTORREDO-TAVR International Registry. Presented by Syed Zaid.
TVT Featured Clinical Research
Clinical Science Theater, Thursday, June 9, 2022, 10:30 am – noon CDT
• Prosthetic Valve Endocarditis After TAVR: Analysis of the Society of Thoracic Surgeons Database. Presented by Shinichi Fukuhara.
• Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Latest-Generation Self-Expanding Valves: Insights From the NEOPRO and NEOPRO-2 Registries. Presented by Andrea Scotti.
• Outcomes of Transcatheter Mitral Valve Replacement Versus Edge-to-Edge Repair in Secondary Mitral Regurgitation Patients According to Adapted COAPT Inclusion Criteria. Presented by Sebastian Ludwig.
• Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A Systematic Review and Meta-Analysis. Presented by Augustin Coisne.
• First in Human Clinical Experience With AMEND Annuloplasty for Mitral Repair. Presented by David Meerkin.
• Comparative Effectiveness of Post-procedure Medications Following Left Atrial Appendage (LAA) Occlusion: A DAPT Analysis With Watchman FLX. Presented by Megan Coylewright.
Additional TVT Structural Heart Meeting Coverage:
VIDEO: The state of TAVR in 2022 Interview with Michael Mack, MD
VIDEO: What is needed to build a structural heart program — Interview with Charles Davidson, MD
VIDEO: Transcatheter tricuspid devices likely to gain FDA clearance before new mitral advances — Azeem Latib, MD
VIDEO: Advances in transcatheter tricuspid and mitral valve technology — Interview with Anita Asgar, MD
VIDEO: Advances in left atrial appendage occlusion technology — Interview with Devi Nair, MD
New LAA occluder technology and the debate on echo vs. CT image guidance
VIDEO: Overview of intra-atrial shunts to treat heart failure — Interview with Peter Fail, MD
VIDEO: Transcatheter myectomy to prevent LVOT obstruction in mitral valve replacement — Interview with Adam Greenbaum, MD
VIDEO: TAVR's long-term impact on patient care — Interview with Azeem Latib, MD
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com